The offering is dilutive at a discount to current market price, which may pressure shares near-term. The concurrent private placement suggests continued capital needs. Traders should monitor for potential downward pressure on the stock price and assess whether the raised capital extends the company's runway sufficiently given its pre-revenue status and recent insider selling.
Price Chart
Executive Summary
Polyrizon Ltd. (PLRZ) is conducting a follow-on offering to raise approximately $2.3 million in net proceeds by selling 87,777 ordinary shares at $9.00 per share and 190,000 pre-funded warrants at $8.99999 each. The company is an emerging growth biotech firm focused on nasal hydrogel-based medical devices for allergy and viral protection, with no current revenue. The offering includes a concurrent private placement of additional warrants, and proceeds will be used for general corporate purposes, R&D, and strategic initiatives.
Key Facts
- Offering 87,777 ordinary shares at $9.00 per share and 190,000 pre-funded warrants at $8.99999 each
- Gross proceeds of $2,499,991.10, with net proceeds of $2,299,991.82 after placement agent fees and expenses
- Concurrent private placement of 111,111 PIPE pre-funded warrants and 388,888 ordinary share warrants
- Company is a development-stage biotech with no revenue, focused on nasal hydrogel medical devices
- Recent insider activity shows 6 sells totaling $133K in the past 30 days
- Stock price at $12.30 on April 6, 2026, above the $9.00 offering price
Financial Impact
Raises approximately $2.3 million in net proceeds, representing about 12.8% of the company's $18 million market cap
Risk Factors
- Dilution from new share issuance
- Ongoing conflict in Israel affecting operations
- No current revenue and history of losses
- Regulatory risks for FDA approval of product candidates
- Recent insider selling activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-041507 |
| Document: 0001213900-26-041507-index-headers.html | 0001213900-26-041507 |
| Document: 0001213900-26-041507-index.html | 0001213900-26-041507 |
| Document: 0001213900-26-041507.txt | 0001213900-26-041507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.96 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers